Isavuconazonium

CHEMBL1183349 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
717.8 g/mol
LogP
4.1
Phase
4

This prodrug is rapidly converted in the body to isavuconazole, a broad-spectrum antifungal medication used to treat serious invasive fungal infections caused by Aspergillus and Mucor species in patients with weakened immune systems. The prodrug formulation improves water solubility for intravenous administration.

น้ำหนักโมเลกุล

717.8000 g/mol

LogP

4.10

TPSA

188.00 Ų

Lipinski RO5

ไม่ผ่าน

กลไกการออกฤทธิ์

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CNCC(=O)OCc1cccnc1N(C)C(=O)OC(C)[n+]1cnn(C[C@](O)(c2cc(F)ccc2F)[C@@H](C)c2nc(-c3ccc(C#N)cc3)cs2)c1

InChI

InChI=1S/C35H35F2N8O5S/c1-22(33-42-30(18-51-33)25-9-7-24(15-38)8-10-25)35(48,28-14-27(36)11-12-29(28)37)19-45-21-44(20-41-45)23(2)50-34(47)43(4)32-26(6-5-13-40-32)17-49-31(46)16-39-3/h5-14,18,20-23,39,48H,16-17,19H2,1-4H3/q+1/t22-,23?,35+/m0/s1

Molecular Formula

C35H35F2N8O5S+

HBD / HBA

2 / 13

พันธะที่หมุนได้

15

อะตอมหนัก

51

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

This prodrug is rapidly converted in the body to isavuconazole, a broad-spectrum antifungal medication used to treat serious invasive fungal infections caused by Aspergillus and Mucor species in patients with weakened immune systems. The prodrug formulation improves water solubility for intravenous administration.

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Yes, Isavuconazonium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1183349. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 6918606. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.